Silencing FAT10 inhibits metastasis of osteosarcoma

Ma,Chengbin; Zhang,Zhiyu; Cui,Yan; Yuan,Hongmou; Wang,Feng

doi:10.3892/ijo.2016.3549

Silencing FAT10 inhibits metastasis of osteosarcoma

Authors:
- Chengbin Ma
- Zhiyu Zhang
- Yan Cui
- Hongmou Yuan
- Feng Wang
View Affiliations

Affiliations: Department of Spine Surgery, Department of Orthopedics, The Fourth Affiliated Hospital, China Medical University, Huanggu, Shenyang, Liaoning 110033, P.R. China, Department of Joint and Oncological Surgery, Department of Orthopedics, The Fourth Affiliated Hospital, China Medical University, Huanggu, Shenyang, Liaoning 110033, P.R. China, Department of Joint Surgery, Department of Orthopedics, The Fourth Affiliated Hospital, China Medical University, Huanggu, Shenyang, Liaoning 110033, P.R. China, Department of Traumatology, Department of Orthopedics, The Fourth Affiliated Hospital, China Medical University, Huanggu, Shenyang, Liaoning 110033, P.R. China
Published online on: June 1, 2016 https://doi.org/10.3892/ijo.2016.3549
Pages: 666-674

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis is the main challenge of osteosarcoma treatment. Herein, we first reveal the oncogenic role of FAT10 in metastasis of osteosarcoma. FAT10 was upregulated in osteosarcoma, especially in metastatic osteosarcoma. High level of FAT10 was associated with poorer prognosis of osteosarcoma patients. Moreover, Transwell and Matrigel assays revealed that silencing FAT10 significantly inhibited the invasive and migratory abilities of osteosarcoma cells. Metastasis assay in vivo showed that silencing FAT10 decreased the number of mice with distant metastasis. We also found that FAT10 may act its oncogenic functions through regulating HOXB9. Collectively, the results suggested that FAT10 may be a novel therapeutic target for osteosarcoma patients.

View Figures

View References

1	Schwab JH, Springfield DS, Raskin KA, Mankin HJ and Hornicek FJ: What's new in primary bone tumors. J Bone Joint Surg Am. 94:1913–1919. 2012. View Article : Google Scholar : PubMed/NCBI
2	Cho Y, Jung GH, Chung SH, Kim JY, Choi Y and Kim JD: Long-term survivals of stage IIb osteosarcoma: A 20-year experience in a single institution. Clin Orthop Surg. 3:48–54. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lewis VO: What's new in musculoskeletal oncology. J Bone Joint Surg Am. 91:1546–1556. 2009. View Article : Google Scholar : PubMed/NCBI
4	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wada T, Isu K, Takeda N, Usui M, Ishii S and Yamawaki S: A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: Preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology. 53:221–227. 1996. View Article : Google Scholar : PubMed/NCBI
6	Dikic I, Wakatsuki S and Walters KJ: Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol. 10:659–671. 2009. View Article : Google Scholar
7	Raasi S, Schmidtke G and Groettrup M: The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem. 276:35334–35343. 2001. View Article : Google Scholar : PubMed/NCBI
8	Hipp MS, Kalveram B, Raasi S, Groettrup M and Schmidtke G: FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol. 25:3483–3491. 2005. View Article : Google Scholar : PubMed/NCBI
9	Ren J, Wang Y, Gao Y, Mehta SB and Lee CG: FAT10 mediates the effect of TNF-α in inducing chromosomal instability. J Cell Sci. 124:3665–3675. 2011. View Article : Google Scholar : PubMed/NCBI
10	Merbl Y, Refour P, Patel H, Springer M and Kirschner MW: Profiling of ubiquitin-like modifications reveals features of mitotic control. Cell. 152:1160–1172. 2013. View Article : Google Scholar : PubMed/NCBI
11	Ji F, Jin X, Jiao CH, Xu QW, Wang ZW and Chen YL: FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging. World J Gastroenterol. 15:2228–2233. 2009. View Article : Google Scholar : PubMed/NCBI
12	Lee CG, Ren J, Cheong IS, Ban KH, Ooi LL, Yong Tan S, Kan A, Nuchprayoon I, Jin R, Lee KH, et al: Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene. 22:2592–2603. 2003. View Article : Google Scholar : PubMed/NCBI
13	Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K and Groettrup M: Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene. 27:6068–6074. 2008. View Article : Google Scholar
14	Sun GH, Liu YD, Yu G, Li N, Sun X and Yang J: Increased FAT10 expression is related to poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol. 35:5167–5171. 2014. View Article : Google Scholar : PubMed/NCBI
15	Yuan J, Tu Y, Mao X, He S, Wang L, Fu G, Zong J and Zhang Y: Increased expression of FAT10 is correlated with progression and prognosis of human glioma. Pathol Oncol Res. 18:833–839. 2012. View Article : Google Scholar : PubMed/NCBI
16	Yuan R, Wang K, Hu J, Yan C, Li M, Yu X, Liu X, Lei J, Guo W, Wu L, et al: Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying β-catenin degradation. Cancer Res. 74:5287–5300. 2014. View Article : Google Scholar : PubMed/NCBI
17	Abate-Shen C: Deregulated homeobox gene expression in cancer: Cause or consequence? Nat Rev Cancer. 2:777–785. 2002. View Article : Google Scholar : PubMed/NCBI
18	Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladany M, Gerald WL and Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
19	Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco M, Wijendran V, Shioda T, et al: HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA. 107:1100–1105. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wen M, Kwon Y, Wang Y, Mao JH and Wei G: Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget. 6:25226–25239. 2015. View Article : Google Scholar : PubMed/NCBI
21	Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, Fan S, Lal B, Laterra J, Schiff D, et al: Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest. 88:98–111. 2008. View Article : Google Scholar
22	Gao Y, Theng SS, Zhuo J, Teo WB, Ren J and Lee CG: FAT10, an ubiquitin-like protein, confers malignant properties in non-tumorigenic and tumorigenic cells. Carcinogenesis. 35:923–934. 2014. View Article : Google Scholar
23	Liu L, Dong Z, Liang J, Cao C, Sun J, Ding Y and Wu D: As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3β pathway. Oncogene. 33:909–920. 2014. View Article : Google Scholar
24	Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, Nijman IJ, Koster J, Santo EE, Welboren W, et al: Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol. 28:2732–2744. 2008. View Article : Google Scholar : PubMed/NCBI
25	Miki T, Yasuda SY and Kahn M: Wnt/β-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev. 7:836–846. 2011. View Article : Google Scholar : PubMed/NCBI
26	Lai TY, Su CC, Kuo WW, Yeh YL, Kuo WH, Tsai FJ, Tsai CH, Weng YJ, Huang CY and Chen LM: β-catenin plays a key role in metastasis of human hepatocellular carcinoma. Oncol Rep. 26:415–422. 2011.PubMed/NCBI
27	Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG and Hung MC: Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 97:4262–4266. 2000. View Article : Google Scholar : PubMed/NCBI
28	Polakis P: The oncogenic activation of beta-catenin. Curr Opin Genet Dev. 9:15–21. 1999. View Article : Google Scholar : PubMed/NCBI
29	Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 275:1790–1792. 1997. View Article : Google Scholar : PubMed/NCBI
30	Aberle H, Bauer A, Stappert J, Kispert A and Kemler R: beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16:3797–3804. 1997. View Article : Google Scholar : PubMed/NCBI